04 / SAFETY & RESPONSIBLE READING
Safety belongs in
every conversation.
Every substance has a context. Risk can depend on formulation, exposure, health conditions, interactions and the quality of available evidence.
Know the limitations
A lack of reported harms is not proof of safety. Information may be limited, especially for new or poorly studied substances.
Understand regulatory status
Approval applies to specific products and indications in specific jurisdictions. Research material is not equivalent to an approved medicine.
Seek qualified guidance
This website is for education, not diagnosis, treatment, prescribing or individual medical advice. Speak to a qualified professional about personal concerns.
Separate the risks.
Pharmacological effects, product identity and microbiological quality are different questions. A well-documented laboratory result does not establish suitability for use. The FDA’s unapproved GLP-1 information provides US-specific product-quality context; it is not a worldwide legal summary.
- FDA — concerns with unapproved GLP-1 drugs ↗US regulatory and product-quality context; subject to change.
- DailyMed — EGRIFTA WR US prescribing information ↗Specific US product and indication; not a global approval statement.
CONTINUE EXPLORING